Cure: FDA approves tablet form of blood cancer treatment
UC expert says more patients may potentially benefit from approval
Following positive results of clinical trials, the Food and Drug Administration recently approved a tablet version of a drug called Calquence for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL) and previously treated relapsed or refractory mantle cell lymphoma (MCL).
The drug was previously approved in capsule form, but the tablet form is able to be given to patients who are also taking drugs that reduce gastric acid.
"Patients with blood cancers like chronic lymphocytic leukemia and mantle cell lymphoma are often older and may face multiple medical conditions that may need intervention, including acid reflux or peptic ulcer disease,” John Byrd, MD, University of Cincinnati Cancer Center member, Gordon and Helen Hughes Taylor Endowed Chair and professor in the Department of Internal Medicine in UC's College of Medicine and a UC Health physician, told the publication Cure. “This provides another option for some patients with chronic lymphocytic leukemia and relapsed or refractory mantle cell lymphoma, enabling more patients to potentially benefit from this treatment.”
Read the Cure article.
Featured photo of John Byrd, MD. Photo/University of Cincinnati.
Related Stories
UC joins novel bipolar research and clinical care network
March 12, 2025
The University of Cincinnati is one of four new national institutions to receive $2.3 million each to join the Breakthrough Discoveries for Thriving with Bipolar Disorder (BD²) Integrated Network, a collaborative research and clinical care model with a mission to improve care, interventions and outcomes for people living with bipolar disorder.
UC Day of Giving connects Bearcats across the globe
Event: April 8, 2025 12:00 PM
For 24 hours on April 8-9, this celebration underscores the profound impact of philanthropy and its ability to transform the UC and UC Health community.
Biomedical engineer studying blunt and blast brain injuries
March 11, 2025
Olga Liaudanskaya, assistant professor of biomedical engineering at the University of Cincinnati, always dreamed of being a scientist. After finishing her graduate degree in materials science and engineering in Italy, she came to the United States for her postdoctoral program, where her research focused on the brain. This led her to a faculty position at UC’s College of Engineering and Applied Science. Recently, she was awarded funding from the Department of Defense for a project on the molecular mechanisms triggered by blunt and blast brain injuries.